Athersys Inc. (ATHX) Tacks Two New Patents to its Intellectual Property Portfolio
Biopharmaceutical company Athersys Inc. yesterday announced the addition of two patents to its broad intellectual property portfolio, now consisting of 14 granted patents and more than 120 global patent applications around its stem cell technology and MultiStem product platform. Athersys was recently granted U.S. patent 7,659,118 that covers the company’s MultiStem technology and non-embryonic multipotent stem cells, including their isolation, expansion, and related pharmaceutical compositions. The company has also been granted EP patent EP1218489B1 that covers non-embryonic pluripotent stem cells, including their isolation, expansion and usage. In its trials, MultiStem® has demonstrated therapeutic potential to treat a broad range of…